Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0002149521-26-000002
Filing Date
2026-08-11
Accepted
2026-08-11 17:03:28
Documents
2
X0202

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 12308
2 JOINT FILING AGREEMENT ex-99-08112026_090830.htm EX-99.1 4219
  Complete submission text file 0002149521-26-000002.txt   18347
Mailing Address 105 W FIRST ST. BOSTON MA 02127
Business Address 105 W FIRST ST. BOSTON MA 02127 (206) 707-0340
Avalyn Pharma Inc. (Subject) CIK: 0001540171 (see all company filings)

EIN.: 452463191 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-95651 | Film No.: 261264259
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O NORWEST VENTURE PARTNERS 1300 EL CAMINO REAL, SUITE 200 MENLO PARK CA 94025
Business Address C/O NORWEST VENTURE PARTNERS 1300 EL CAMINO REAL, SUITE 200 MENLO PARK CA 94025 6503218000
Norwest Venture Partners XV, LP (Filed by) CIK: 0002149521 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G